118 related articles for article (PubMed ID: 8757754)
1. Stromelysin-3 mRNA associated with myofibroblasts is overexpressed in aggressive basal cell carcinoma and in dermatofibroma but not in dermatofibrosarcoma.
Undén AB; Sandstedt B; Bruce K; Hedblad M; Stahle-Bäckdahl M
J Invest Dermatol; 1996 Aug; 107(2):147-53. PubMed ID: 8757754
[TBL] [Abstract][Full Text] [Related]
2. Expression of stromelysin 3 in the stromal elements of human basal cell carcinoma.
Wagner SN; Ruhri C; Kunth K; Holecek BU; Goos M; Höfler H; Atkinson MJ
Diagn Mol Pathol; 1992 Sep; 1(3):200-5. PubMed ID: 1342967
[TBL] [Abstract][Full Text] [Related]
3. Stromelysin 3 expression: a useful marker for the differential diagnosis dermatofibroma versus dermatofibrosarcoma protuberans.
Cribier B; Noacco G; Peltre B; Grosshans E
J Am Acad Dermatol; 2002 Mar; 46(3):408-13. PubMed ID: 11862177
[TBL] [Abstract][Full Text] [Related]
4. Tenascin expression in cutaneous fibrohistiocytic tumors. Immunohistochemical investigation of 24 cases.
Franchi A; Santucci M
Am J Dermatopathol; 1996 Oct; 18(5):454-9. PubMed ID: 8902090
[TBL] [Abstract][Full Text] [Related]
5. The expression levels and the differential expression of transforming growth factor-beta receptors in dermatofibroma and dermatofibrosarcoma protuberans.
Kubo M; Ihn H; Yamane K; Tamaki K
Br J Dermatol; 2006 May; 154(5):919-25. PubMed ID: 16634896
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of stromelysin-3 in basal cell carcinomas.
Majmudar G; Nelson BR; Jensen TC; Voorhees JJ; Johnson TM
Mol Carcinog; 1994 Jan; 9(1):17-23. PubMed ID: 8297480
[TBL] [Abstract][Full Text] [Related]
7. p53 protein immunoreactivity in fibrohistiocytic tumors of the skin.
Lee CS; Chou ST
Pathology; 1998 Aug; 30(3):272-5. PubMed ID: 9770192
[TBL] [Abstract][Full Text] [Related]
8. Differential patterns of stromelysin-2 (MMP-10) and MT1-MMP (MMP-14) expression in epithelial skin cancers.
Kerkelä E; Ala-aho R; Lohi J; Grénman R; M-Kähäri V; Saarialho-Kere U
Br J Cancer; 2001 Mar; 84(5):659-69. PubMed ID: 11237387
[TBL] [Abstract][Full Text] [Related]
9. Stromelysin-3 (ST-3): immunohistochemical characterization of the matrix metalloproteinase (MMP)-11 in benign and malignant skin tumours and other skin disorders.
Thewes M; Worret WI; Engst R; Ring J
Clin Exp Dermatol; 1999 Mar; 24(2):122-6. PubMed ID: 10233668
[TBL] [Abstract][Full Text] [Related]
10. GREM1 is expressed in the cancer-associated myofibroblasts of basal cell carcinomas.
Kim HS; Shin MS; Cheon MS; Kim JW; Lee C; Kim WH; Kim YS; Jang BG
PLoS One; 2017; 12(3):e0174565. PubMed ID: 28346486
[TBL] [Abstract][Full Text] [Related]
11. Stromal expression of actin is a marker of aggressiveness in basal cell carcinoma.
Adegboyega PA; Rodriguez S; McLarty J
Hum Pathol; 2010 Aug; 41(8):1128-37. PubMed ID: 20381122
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical detection of p53 in epidermal proliferations overlying dermatofibromas.
Haerslev T; Rossen K; Hou-Jensen K; Jacobsen GK
Acta Derm Venereol; 1995 May; 75(3):187-9. PubMed ID: 7653177
[TBL] [Abstract][Full Text] [Related]
13. A switch from stromal to tumor cell expression of stromelysin-1 mRNA associated with the conversion of squamous to spindle carcinomas during mouse skin tumor progression.
Wright JH; McDonnell S; Portella G; Bowden GT; Balmain A; Matrisian LM
Mol Carcinog; 1994 Aug; 10(4):207-15. PubMed ID: 8068181
[TBL] [Abstract][Full Text] [Related]
14. Matrix-degrading metalloproteinases in tumor progression.
Matrisian LM; Wright J; Newell K; Witty JP
Princess Takamatsu Symp; 1994; 24():152-61. PubMed ID: 8983072
[TBL] [Abstract][Full Text] [Related]
15. Breast-cancer-associated stromelysin-3 gene is expressed in basal cell carcinoma and during cutaneous wound healing.
Wolf C; Chenard MP; Durand de Grossouvre P; Bellocq JP; Chambon P; Basset P
J Invest Dermatol; 1992 Dec; 99(6):870-2. PubMed ID: 1469302
[TBL] [Abstract][Full Text] [Related]
16. [Cellular fibrous histiocytoma: a clinicopathologic analysis of 27 cases].
Zhong YP; Wang J
Zhonghua Bing Li Xue Za Zhi; 2013 Mar; 42(3):153-7. PubMed ID: 23769432
[TBL] [Abstract][Full Text] [Related]
17. A study of CD117 expression in dermatofibrosarcoma protuberans and cellular dermatofibroma.
Labonte S; Hanna W; Bandarchi-Chamkhaleh B
J Cutan Pathol; 2007 Nov; 34(11):857-60. PubMed ID: 17944726
[TBL] [Abstract][Full Text] [Related]
18. Metallothionein expression in basaloid proliferations overlying dermatofibromas and in basal cell carcinomas.
Rossen K; Haerslev T; Hou-Jensen K; Jacobsen GK
Br J Dermatol; 1997 Jan; 136(1):30-4. PubMed ID: 9039291
[TBL] [Abstract][Full Text] [Related]
19. Low proliferative activity in common dermatofibroma does not necessarily guarantee a low proliferation in all dermatofibroma variants.
Fernandez-Flores A
Arch Pathol Lab Med; 2008 Feb; 132(2):160; author reply 160-1. PubMed ID: 18251566
[No Abstract] [Full Text] [Related]
20. Expression of embryonic stem cell markers SOX2 and nestin in dermatofibrosarcoma protuberans and dermatofibroma.
Sellheyer K; Nelson P; Patel RM
J Cutan Pathol; 2011 May; 38(5):415-9. PubMed ID: 21251041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
